The Global Pharmaceutical Contract Manufacturing market is estimated to grow at a CAGR of 6% in the first-half of the forecast period

Wednesday 14 November 2018, Amsterdam

Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing - lower costs, increased flexibility and external expertise - to focus resources on core competencies in drug development and marketing. CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug. The market-leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.

This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain’s research and analysis explore opportunities and challenges for the top 50 pharma contract manufacturing organisations.

The lead analyst of the report commented "Our research has identified two major trends for leading API manufacturers in the coming 10 years: generics and HPAPIs. Demand for generic drugs is rising in developed markets - driven by the need to cut healthcare spending and patent expiries for major blockbusters - and in emerging markets - driven by rising disease prevalence and greater access to healthcare.

Demand will also rise for custom API manufacturing, particularly in the complex API and HPAPI market sectors. Our team believes that this market trend will be driven by increasing demands for targeted, small molecule therapies in chronic diseases, such as cancer."

Leading companies featured in the report include AbbVie Contract Manufacturing, Aenova Group, Aesica Pharmaceuticals, Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Alcami Corporation, Alkermes plc, Almac Group, Amatsigroup, Aurobindo Pharma Ltd., Avid Bioservices Inc., Bayer AG, Baxter Biopharma Solutions, Biomay AG, Boehringer Ingelheim GmbH, Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Cardinal Health, Corden Pharmaceutical, Daito Pharmaceutical, Delpharm, Divis Laboratories Ltd., Dr. Reddy’s Laboratories Ltd., DPT Laboratories, Esteve Química, Evonik Degussa, Famar Health Care Services, Fareva, Fujifilm Diosynth Biotechnologies UK Ltd, GlaxoSmithKline plc, Huapont Medical, Lonza Group Ltd., Nipro Corporation, Paragon Bioservices Inc, Patheon Inc, Pfizer Inc./Pfizer CentreSource (PCS), Piramal Healthcare L, Recipharm A, Roche, Royal DSM NV, Shandong Xinhua Pharmaceutical, Siegfried, Teva API, Therapure Biopharma Inc., UPM Pharmaceuticals Inc., Vetter Pharmacuticals, Xcelience LLC, Xcellerex LLC, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceuticals